NRx Pharmaceuticals, Inc. (NRXP) NASDAQ
4.62
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.62
+0(+0.00%)
Currency In USD
| Previous Close | 4.62 |
| Open | 4.65 |
| Day High | 5.06 |
| Day Low | 4.58 |
| 52-Week High | 5.06 |
| 52-Week Low | 1.62 |
| Volume | 2.06M |
| Average Volume | 1.13M |
| Market Cap | 79.86M |
| PE | -4.44 |
| EPS | -1.04 |
| Moving Average 50 Days | 2.91 |
| Moving Average 200 Days | 2.58 |
| Change | 0 |
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.Now acc
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
GlobeNewswire Inc.
Mar 02, 2026 12:00 PM GMT
Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuro
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER)Oral guidance received at the meeting provides a p